Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
MAUL, Julia-Tatjana
FROEHLICH, Fabienne
MAUL, Lara Valeska
STUNNENBERG, Rieka
VALENZUELA, Fernando
CRUZ, Claudia De La
VERA-KELLET, Cristian
ARMIJO, Daniela
CESAR, Wagner G.
CARVALHO, Andre
Citação
BRITISH JOURNAL OF DERMATOLOGY, v.188, n.4, p.533-541, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Brazil and Chile are lacking. Understanding the availability and limiting factors of access to treatments can help to improve patient care and decrease long-term healthcare costs. Objectives In association with the Global Psoriasis Atlas, this cross-sectional survey study analysed the availability and insurance reimbursement of systemic treatments for adult patients with psoriasis in Brazil and Chile. Methods A multicentre, cross-sectional Global Healthcare Study on Psoriasis was performed in Brazil and Chile in 2020. For each eligible adult patient with psoriasis, doctors and nurses completed a 48-item questionnaire about clinical aspects of psoriasis including the Psoriasis Area Severity Index (PASI), body surface area (BSA) score and the Dermatology Life Quality Index (DLQI), as well as the availability of systemic treatments and insurance reimbursement status. Between-country differences were compared with Wilcoxon rank sum tests for continuous variables, and a chi(2)-test or Fisher's exact test, where appropriate, for categorical variables. The median and interquartile range (IQR) was calculated for non-normal distributed data. Results A total of 1424 patients with psoriasis from 43 centres [27 centres in Brazil (n = 826) and 16 in Chile (n = 598)], were included with a mean (SD) age of 49.1 (16.3) and 49.2 (15.1) years, respectively. Unstratified analyses revealed that patients with psoriasis in Chile had more severe disease than those in Brazil [PASI 11.6 vs. 8.4 (P < 0.001) and BSA 14.7 vs. 12.0 (P = 0.003), respectively]. For patients with moderate-to-severe psoriasis, defined as PASI and/or BSA >= 10, systemic nonbiologic drugs were available (81.2% in Brazil and 65.3% in Chile, P <= 0.001), but only 37.0% of patients in Brazil and 27.3% in Chile received biologics (P = 0.01). Lack of availability and/or lack of insurance reimbursement for biologic drugs for patients with moderate-to-severe psoriasis was reported for 22.2% (50 of 225) in Brazil and 67.9% (148 of 218) in Chile (P < 0.001). Patients with no access to biologic therapies due to lack of availability/insurance reimbursement had a median PASI of 9.15 (IQR 3.00-14.25) in Brazil and 12.0 (IQR 5.00-19.00) in Chile (P = 0.007), as well as a median BSA of 7.0 (IQR 3.00-15.00) and 12.0 (IQR 5.00-22.50) (P = 0.002), and median DLQI of 11.0 (6.00-15.00) and 21.0 (6.50-25.00) (P = 0.007), respectively. Conclusions Chilean patients had significantly more severe psoriasis compared with Brazilian patients in our study. While nonbiologic treatments for moderate-to-severe psoriasis were available in both LA countries, there is a high need for improvement in access to more effective psoriasis treatments including biologics. Our results highlight a significant gap between treatment recommendations in international psoriasis guidelines and real-world situations in Brazil and Chile.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/54199
Referências
  1. Augustin M, 2014, J DTSCH DERMATOL GES, V12, P48, DOI 10.1111/ddg.12233
  2. Burden AD, 2012, BRIT J DERMATOL, V166, P545, DOI 10.1111/j.1365-2133.2012.10835.x
  3. Carey G., 2019, NEUROL SCI
  4. Carvalho A., 2020, VALUE HEALTH, V12, P231
  5. Chouela E., 2016, DERMATOL ONLINE J, V22, P13030
  6. Dauden E, 2018, J EUR ACAD DERMATOL, V32, P2058, DOI 10.1111/jdv.15177
  7. Egeberg A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028116
  8. Espinoza Luis R, 2012, J Rheumatol, V39, P445, DOI 10.3899/jrheum.111246
  9. Frizzo H., 2020, TRANSBOUND EMERG DIS
  10. Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3
  11. Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6
  12. Hernandez-Vasquez A, 2017, J EUR ACAD DERMATOL, V31, P1991, DOI 10.1111/jdv.14393
  13. Kimball AB, 2010, J EUR ACAD DERMATOL, V24, P989, DOI 10.1111/j.1468-3083.2010.03705.x
  14. Kogan N, 2019, INT J DERMATOL, V58, P4, DOI 10.1111/ijd.14471
  15. Lecaros C, 2021, CLIN EXP DERMATOL, V46, P1262, DOI 10.1111/ced.14713
  16. Lopes LC, 2014, REV SAUDE PUBL, V48, P651, DOI 10.1590/S0034-8910.2014048005109
  17. Manolis AA, 2019, INT REV IMMUNOL, V38, P33, DOI 10.1080/08830185.2018.1539084
  18. Mattei PL, 2014, J EUR ACAD DERMATOL, V28, P333, DOI 10.1111/jdv.12106
  19. Maul JT, 2021, BRIT J DERMATOL, V185, P1160, DOI 10.1111/bjd.20387
  20. Maul JT, 2019, J EUR ACAD DERMATOL, V33, P700, DOI 10.1111/jdv.15324
  21. Maul JT, 2016, DERMATOLOGY, V232, P640, DOI 10.1159/000452740
  22. Menter A, 2020, J AM ACAD DERMATOL, V82, P1445, DOI 10.1016/j.jaad.2020.02.044
  23. Nast A, 2020, J EUR ACAD DERMATOL, V34, P2461, DOI 10.1111/jdv.16915
  24. Nast A, 2021, J DTSCH DERMATOL GES, V19, P1092, DOI 10.1111/ddg.14507
  25. Ogawa K, 2019, J INVEST DERMATOL, V139, P1397, DOI 10.1016/j.jid.2018.11.023
  26. Oji V, 2015, CLIN EXP RHEUMATOL, V33, pS14
  27. Parisi R, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1590
  28. Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339
  29. Pithadia DJ, 2019, CUTIS, V104, P12
  30. R Development Core Team, 2008, R LANG ENV STAT COMP
  31. Baeta IGR, 2014, AN BRAS DERMATOL, V89, P735, DOI 10.1590/abd1806-4841.20142874
  32. Romiti R, 2021, AN BRAS DERMATOL, V96, P778, DOI 10.1016/j.abd.2021.03.007
  33. Romiti R, 2018, J DERMATOL TREAT, V29, P775, DOI 10.1080/09546634.2018.1466023
  34. Romiti R, 2017, INT J DERMATOL, V56, pE167, DOI 10.1111/ijd.13604
  35. Salud Md., 2022, US
  36. Saude Md., 2021, APROVA PROTOCOLO CLI, V18
  37. Strober B, 2020, J AM ACAD DERMATOL, V82, P117, DOI 10.1016/j.jaad.2019.08.026
  38. Takeshita J, 2017, J AM ACAD DERMATOL, V76, P377, DOI 10.1016/j.jaad.2016.07.064
  39. von Stulpnagel CC, 2021, J EUR ACAD DERMATOL, V35, P2166, DOI 10.1111/jdv.17348
  40. Yoshida Kazuki, 2020, CRAN

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/50
Artigos e Materiais de Revistas Científicas - LIM/53